Roxithromycin

Roxithromycin

Error creating thumbnail: File missing
Clinical data
Pregnancy category	? (USA) B1 (Aus)
ATC code	J01FA06 (WHO)
Pharmacokinetic data
Metabolism	Liver
Elimination half-life	12 hours
Identifiers
CAS Number	80214-83-1
PubChem CID	444037
DrugBank	APRD01305
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C41H76N2O15
Molar mass	837.047 g/mol

WikiDoc Resources for Roxithromycin
Articles
Most recent articles on Roxithromycin Most cited articles on Roxithromycin Review articles on Roxithromycin Articles on Roxithromycin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Roxithromycin Images of Roxithromycin Photos of Roxithromycin Podcasts & MP3s on Roxithromycin Videos on Roxithromycin
Evidence Based Medicine
Cochrane Collaboration on Roxithromycin Bandolier on Roxithromycin TRIP on Roxithromycin
Clinical Trials
Ongoing Trials on Roxithromycin at Clinical Trials.gov Trial results on Roxithromycin Clinical Trials on Roxithromycin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Roxithromycin NICE Guidance on Roxithromycin NHS PRODIGY Guidance FDA on Roxithromycin CDC on Roxithromycin
Books
Books on Roxithromycin
News
Roxithromycin in the news Be alerted to news on Roxithromycin News trends on Roxithromycin
Commentary
Blogs on Roxithromycin
Definitions
Definitions of Roxithromycin
Patient Resources / Community
Patient resources on Roxithromycin Discussion groups on Roxithromycin Patient Handouts on Roxithromycin Directions to Hospitals Treating Roxithromycin Risk calculators and risk factors for Roxithromycin
Healthcare Provider Resources
Symptoms of Roxithromycin Causes & Risk Factors for Roxithromycin Diagnostic studies for Roxithromycin Treatment of Roxithromycin
Continuing Medical Education (CME)
CME Programs on Roxithromycin
International
Roxithromycin en Espanol Roxithromycin en Francais
Business
Roxithromycin in the Marketplace Patents on Roxithromycin
Experimental / Informatics
List of terms related to Roxithromycin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Roxithromycin is a semi-synthetic macrolide antibiotic. It is used to treat respiratory tract, urinary and soft tissue infections. Roxithromycin is derived from erythromycin, containing the same 14-membered lactone ring. However, an N-oxime side chain is attached to the lactone ring. It is also currently undergoing clinical trials for the treatment of male-pattern hair loss.

Roxithromycin is available under several brandnames, for example Surlid, Rulide, Biaxsig, Roxar and Roximycin.

History

German pharmaceutical company Hoechst Uclaf brought out roxithromycin in 1987.

Available forms

Roxithromycin is commonly available as tablets or oral suspension.

Mechanism of action

Roxithromycin prevents bacteria from growing, by interfering with their protein synthesis. Roxithromycin binds to the subunit 50S of the bacterial ribosome, and thus inhibits the translocation of peptides. Roxithromycin has similar antimicrobial spectrum as erythromycin, but is more effective against certain gram-negative bacteria, particularly Legionella pneumophila.

Pharmacokinetics

When taken before a meal, roxithromycin is very rapidly absorbed, and diffused into most tissues and phagocytes. Due to the high concentration in phagocytes, roxithromycin is actively transported to the site of infection. During active phagocytosis, large concentrations of roxithromycin are released.

Metabolism

Only a small portion of roxithromycin is metabolised. Most of roxithromycin is secreted unchanged into the bile and some in expired air. Under 10% is excreted into the urine. Roxithromycin's half-life is 12 hours.

Side effects

Most common side effects are gastrointestinal; diarrhoea, nausea, abdominal pain and vomiting. Less common side effects include central or peripheral nervous system events such as headaches, dizziness, vertigo, and also the rarely seen rashes, abnormal liver function values and alteration in senses of smell and taste.

Drug interactions

Roxithromycin has less interactions than erythromycin as it has a lower affinity for cytochrome P450.

Roxithromycin does not interact with hormonal contraceptives, prednisolone, carbamazepine, ranitidine or antacids.

When roxithromycin is administered with theophylline, some studies have shown an increase in the plasma concentration of theophylline. A change in dosage is usually not required but patients with high levels of theophylline at the start of the treatment should have their plasma levels monitored.

Roxithromycin appears to interact with warfarin. This is shown by an increase in prothrombin time (international normalised ratio (INR)) in patients taking roxithromycin and warfarin concurrently. As a consequence, severe bleeding episodes have occurred.